Upstream Bio (NASDAQ:UPB – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
Risk and Volatility
Upstream Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Upstream Bio and MediWound, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
Upstream Bio currently has a consensus target price of $26.67, indicating a potential upside of 859.23%. MediWound has a consensus target price of $33.00, indicating a potential upside of 155.81%. Given Upstream Bio’s higher probable upside, analysts plainly believe Upstream Bio is more favorable than MediWound.
Insider & Institutional Ownership
46.8% of MediWound shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Upstream Bio and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Upstream Bio | -5,712.33% | -57.09% | -54.69% |
| MediWound | -234.98% | -58.44% | -29.62% |
Earnings and Valuation
This table compares Upstream Bio and MediWound”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Upstream Bio | $2.87 million | 53.09 | -$143.44 million | ($3.02) | -0.92 |
| MediWound | $16.96 million | 9.90 | -$23.88 million | ($1.80) | -7.17 |
MediWound has higher revenue and earnings than Upstream Bio. MediWound is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.
Summary
MediWound beats Upstream Bio on 7 of the 13 factors compared between the two stocks.
About Upstream Bio
Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.
About MediWound
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
